I am a Pharmacy graduate from the National University of Singapore (NUS) with a research interest in organic synthesis, toxicology, and infectious diseases. In October 2020, I embarked on my doctoral studies in Chemistry as part of the University of Cambridge’s Syntech CDT.
I have been affiliated with the Agency for Science, Technology, and Research (A*STAR) since 2011, and have worked in the following Research Institutes (RIs):
- Experimental Drug Development Centre (EDDC) (2019 – 2020)
- Bioinformatics Institute (BII) (2017)
- Institute of Bioengineering and Nanotechnology (now IBB) (2015)
- Institute of Materials Research and Engineering (IMRE) (2011 – 2012)
In NUS, my undergraduate research work consisted of two research projects that revolved around tuberculosis: 1) discovering antitubercular agents that utilise new mechanisms of action against Mycobacterium tuberculosis, and 2) finding ways to reduce side effects of the tuberculosis drug regimens in use.
Mixed Alkyl/Aryl Phosphonates Identify Metabolic Serine Hydrolases as Antimalarial Targets
Optical Control of G-Actin with a Photoswitchable Latrunculin
SQ3370, the first clinical click chemistry-activated cancer therapeutic, shows safety in humans and translatability across species
DNA-enhanced CuAAC ligand enables live-cell detection of intracellular biomolecules
Multifunctional fluorophores for live-cell imaging and affinity capture of proteins
Selective inhibitors of JAK1 targeting a subtype-restricted allosteric cysteine
High-throughput aminoacyl-tRNA synthetase engineering for genetic code expansion in yeast
Discovery and visualization of uncharacterized drug-protein adducts using mass spectrometry
The Design, Synthesis, and Evaluation of Hypoxia-Activated Prodrugs of the KDAC Inhibitor Panobinostat
Design of smart antibody mimetics with photosensitive switches
Accelerated erythrocyte senescence causes dose-limiting anemia of antimalarial enolase inhibitors
Systematic Engineering of Artificial Metalloenzymes for New-to-Nature Reactions
COVID-19 / SARS-CoV-2 preprints
List of important preprints dealing with the ongoing coronavirus outbreak. See http://covidpreprints.com for additional resources and timeline, and https://connect.biorxiv.org/relate/content/181 for full list of bioRxiv and medRxiv preprints on this topic
|Dey Lab, Zhang-He Goh
Drug use in special populations
Any drugs that are being used in special populations: Patients with liver and kidney failure, in paediatrics, in geriatrics, and in pregnant or lactating patients. Includes the discovery of factors that could potentially affect drug use in these special populations.
Toxicology of toxicants, existing therapeutics, and investigational drugs
Preprints that describe the toxicology of environmental pollutants and existing and upcoming drugs. Includes both toxicokinetics and toxicodynamics, as well as technological improvements that will help in the characterisation of this field.
Antimicrobials: Discovery, clinical use, and development of resistance
Preprints that describe the discovery of new antimicrobials and any improvements made regarding their clinical use. Includes preprints that detail the factors affecting antimicrobial selection and the development of antimicrobial resistance.
Anticancer agents: Discovery and clinical use
Preprints that describe the discovery of anticancer agents and their clinical use. Includes both small molecules and macromolecules like biologics.
Advances in Drug Delivery
Advances in formulation technology or targeted delivery methods that describe or develop the distribution of small molecules or large macromolecules to specific parts of the body.